PS
RCKT icon

Principal Securities’s Rocket Pharmaceuticals RCKT Stock Holding History

Principal Securities’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42
Closed -$137 – 3019
2025
Q3 		$137 Buy
+42
New +$132 ﹤0.01% 3678
2024
Q1 		– Sell
-9
Closed -$270 – 3374
2023
Q4 		$270 Buy
+9
New +$199 ﹤0.01% 3125

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Principal Securities's RCKT Position: Q4 2025 in Review

Principal Securities sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 42 shares — an estimated $137 sold.

Principal Securities first reported a position in RCKT in Q4 2023 and held it in 2 quarters. The position peaked at $270 in Q4 2023. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

  • Principal Securities reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 42 Rocket Pharmaceuticals shares in Q4 2025, an estimated $137.
  • Principal Securities first reported a position in Rocket Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Principal Securities's Rocket Pharmaceuticals position peaked at $270 in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.